Amyloid-beta composite biomarker

1. DPP-4 inhibitors decrease amyloid-beta composite biomarker in humans (-0.5 ± 0.7 vs. 0.0 ± 0.7, P = 0.02).

   “At baseline, users had lower Aβ composite biomarker levels than non‐users (‐0.5 ± 0.7 vs. 0.0 ± 0.7, P = 0.02, Table 1).”

   Humansat baseline in older adults with type 2 diabetesplasman = 43

   Association between DPP‐4 inhibitor use and changes in dementia‐related plasma biomarkers in older adults with type 2 diabetes: post‐hoc analyses of J‐MINT

   AAIC 2025 abstract·25 Dec 2025

More on DPP-4 inhibitors